Literature DB >> 1727795

Anti-pre-S responses and viral clearance in chronic hepatitis B virus infection.

A Budkowska1, P Dubreuil, T Poynard, P Marcellin, M A Loriot, P Maillard, J Pillot.   

Abstract

Serial sera were collected prospectively during the clinical course of 13 HBsAg carriers with chronic liver disease and analyzed for ALT levels, pre-S1 and pre-S2 antigens and corresponding antibodies and other serological hepatitis B virus markers. In five patients, anti-pre-S1 and anti-pre-S2 antibodies became detectable in multiple serum samples, whereas in eight patients anti-pre-S was never detected or only appeared transiently during the follow-up. The first pattern was associated with normalization of ALT levels and undetectable pre-S antigens and viral DNA by the polymerase chain reaction assay at final follow-up. HBsAg clearance occurred in two of the five patients. The second pattern was one of persistence of HBsAg and pre-S antigens, associated with the presence of serum HBV DNA detectable by spot hybridization or polymerase chain reaction regardless of clinical outcome. These findings demonstrate the occurrence of anti-pre-S antibodies in chronic hepatitis B virus-induced liver disease and associate anti-pre-S appearance with the clearance of hepatitis B virus from serum.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727795     DOI: 10.1002/hep.1840150106

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  5 in total

1.  Expression and characterization of the multiplied, recombinant preS1 antigen of hepatitis B virus.

Authors:  M Sidorkiewicz; G Płucienniczak; A Płucienniczak
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

2.  Variations in the S and P regions of the hepatitis B virus genome under immunosuppression in vitro and in vivo.

Authors:  Zhong-Yang Shen; Wei-Ping Zheng; Yong-Lin Deng; Hong-Li Song
Journal:  Viral Immunol       Date:  2012-09-04       Impact factor: 2.257

3.  DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.

Authors:  M L Michel; H L Davis; M Schleef; M Mancini; P Tiollais; R G Whalen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

4.  Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Authors:  D C Whitacre; C J Peters; C Sureau; K Nio; F Li; L Su; J E Jones; M Isogawa; M Sallberg; L Frelin; D L Peterson; D R Milich
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

5.  Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals.

Authors:  Anurag Sankhyan; Chandresh Sharma; Durgashree Dutta; Tarang Sharma; Kunzang Chosdol; Takaji Wakita; Koichi Watashi; Amit Awasthi; Subrat K Acharya; Navin Khanna; Ashutosh Tiwari; Subrata Sinha
Journal:  Sci Rep       Date:  2016-02-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.